NCT04792021View on ClinicalTrials.gov

Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

September 13, 2021

Study Completion Date

April 1, 2022

Conditions
Corona Virus Disease 19 (Covid19)Corona Virus InfectionSevere Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)
Interventions
DRUG

N-acetylcysteine

Oral formulation: 600 mg sachets of N-acetylcysteine

Trial Locations (1)

Unknown

Al Assema Hospital, Cairo

All Listed Sponsors
collaborator

Misr International University

OTHER

lead

Ain Shams University

OTHER

NCT04792021 - Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients | Biotech Hunter | Biotech Hunter